Calm Medical

Calm Medical operates in the neuromodulation and urological medical-device markets, targeting bladder dysfunction with a less invasive alternative to treatments that require surgery or permanently exposed hardware. Its stated differentiation is the combination of tibial nerve stimulation, needle-based placement, external pulse generation, and a fully implanted device that does not require wires or cables to pass through the skin. The system is also designed for outpatient placement and removal without sutures, which could affect procedural burden and patient acceptance if clinical evidence supports those claims. The company’s focus on neurogenic bladder and overactive bladder gives it a narrower initial application than broad neuromodulation platforms, but it also creates a defined clinical use case. Calm Medical’s pursuit of a Class II FDA pathway and its $1.73 million Department of Defense-supported neurogenic bladder study indicate a strategy centered on evidence generation rather than commercial scale. Its competitive position therefore remains development-stage and dependent on clinical outcomes, regulatory progress, and adoption by urology specialists.

Calm Medical’s trajectory is centered on advancing a focused medical-device program from platform development toward clinical validation and regulatory clearance. The principal inflection point identified is its application of Neuronoff’s Injectrode platform to bladder dysfunction, adapting an externally stimulated, fully implanted neuromodulation device for tibial nerve stimulation. A second milestone is the $1.73 million Department of Defense-funded neurogenic bladder study, which provides a defined evidence-generation program and may help establish clinical utility in a population with significant unmet need. The company also describes a Class II FDA pathway, suggesting a regulatory strategy based on clinical evidence and device classification rather than a high-risk implant pathway. Operational growth cannot be quantified: employee counts, hiring activity, financing rounds, product-launch dates, and commercial revenue are not publicly identified in the available profile. There is also no documented funding history from which to infer runway or expansion capacity. Near-term progress is therefore best measured through study execution, regulatory submissions, clinical results, and the transition from prototype or investigational use toward outpatient clinical deployment. The absence of dated launches or workforce data makes the pace of growth uncertain.